[go: up one dir, main page]

NO2516457T3 - - Google Patents

Info

Publication number
NO2516457T3
NO2516457T3 NO10791039A NO10791039A NO2516457T3 NO 2516457 T3 NO2516457 T3 NO 2516457T3 NO 10791039 A NO10791039 A NO 10791039A NO 10791039 A NO10791039 A NO 10791039A NO 2516457 T3 NO2516457 T3 NO 2516457T3
Authority
NO
Norway
Application number
NO10791039A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43601078&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2516457(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of NO2516457T3 publication Critical patent/NO2516457T3/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0387—Animal model for diseases of the immune system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Environmental Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
NO10791039A 2009-12-21 2010-12-17 NO2516457T3 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28856209P 2009-12-21 2009-12-21
PCT/US2010/060925 WO2011084664A1 (en) 2009-12-21 2010-12-17 HUMANIZED FCγ R MICE

Publications (1)

Publication Number Publication Date
NO2516457T3 true NO2516457T3 (de) 2018-08-11

Family

ID=43601078

Family Applications (1)

Application Number Title Priority Date Filing Date
NO10791039A NO2516457T3 (de) 2009-12-21 2010-12-17

Country Status (26)

Country Link
US (9) US8658154B2 (de)
EP (3) EP3336102A3 (de)
JP (4) JP5595517B2 (de)
KR (4) KR102092744B1 (de)
CN (2) CN104232589B (de)
AU (3) AU2010339863B2 (de)
CA (2) CA2784953C (de)
CY (1) CY1120316T1 (de)
DK (1) DK2516457T3 (de)
ES (1) ES2671188T3 (de)
HK (1) HK1257001A1 (de)
HR (1) HRP20180911T1 (de)
HU (1) HUE038684T2 (de)
IL (4) IL220365A (de)
LT (1) LT2516457T (de)
MY (1) MY156743A (de)
NO (1) NO2516457T3 (de)
PL (1) PL2516457T3 (de)
PT (1) PT2516457T (de)
RS (1) RS57280B1 (de)
RU (1) RU2549695C2 (de)
SG (3) SG181690A1 (de)
SI (1) SI2516457T1 (de)
SM (1) SMT201800296T1 (de)
TR (1) TR201808011T4 (de)
WO (1) WO2011084664A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS57280B1 (sr) * 2009-12-21 2018-08-31 Regeneron Pharma Humanizovani fc gamma r miševi
LT2818478T (lt) 2011-10-28 2017-06-12 Regeneron Pharmaceuticals, Inc. Humanizuotas il-6 ir il-6 receptorius
JP2014532399A (ja) * 2011-11-01 2014-12-08 ロシュ グリクアート アーゲー インビボａｄｃｃモデル
ES2884598T3 (es) * 2012-11-05 2021-12-10 Regeneron Pharma Animales no humanos modificados genéticamente y métodos de uso de los mismos
US20150079680A1 (en) 2013-09-18 2015-03-19 Kymab Limited Methods, cells & organisms
SI2908626T1 (sl) * 2013-10-15 2017-02-28 Regeneron Pharmaceuticals, Inc. Humanizirane živali IL-15
WO2015088643A1 (en) 2013-12-11 2015-06-18 Regeneron Pharmaceuticals, Inc. Methods and compositions for the targeted modification of a genome
CA3124228C (en) * 2014-03-21 2024-05-14 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
RS60398B1 (sr) * 2014-04-08 2020-07-31 Regeneron Pharma Ne-humane životinje sa humanizovanim fc-gama receptorima
WO2015184164A1 (en) 2014-05-30 2015-12-03 Regeneron Pharmaceuticals, Inc. Humanized dipeptidyl peptidase iv (dpp4) animals
JP2018500896A (ja) 2014-12-09 2018-01-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ヒト化分化抗原群２７４遺伝子を有する非ヒト動物
FI3282835T3 (fi) * 2015-04-13 2023-07-20 Regeneron Pharma Humanisoituja sirpa-il15-poistogeenisiä hiiriä ja niiden käyttömenetelmiä
CN107529739B (zh) * 2015-04-30 2021-01-08 株式会社特殊免疫研究所 表达人特定分子和人Fcγ受体家族的转基因非人动物
US11879014B2 (en) * 2017-03-17 2024-01-23 Tusk Therapeutics Ltd. Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
CN112105260B (zh) 2018-03-26 2023-04-28 瑞泽恩制药公司 用于测试治疗剂的人源化啮齿动物
JP6935383B2 (ja) * 2018-09-27 2021-09-15 公益財団法人実験動物中央研究所 免疫不全マウス
WO2020067199A1 (ja) * 2018-09-27 2020-04-02 公益財団法人実験動物中央研究所 免疫不全マウス
WO2020172505A1 (en) 2019-02-22 2020-08-27 Regeneron Pharmaceuticals, Inc. Rodents having genetically modified sodium channels and methods of use thereof
CN113614238B (zh) * 2019-03-28 2024-10-22 公益财团法人实中研 免疫缺陷小鼠
KR20230147048A (ko) 2020-12-16 2023-10-20 리제너론 파마슈티칼스 인코포레이티드 인간화 Fc 알파 수용체를 발현하는 마우스
CN114410643B (zh) * 2021-02-02 2024-08-02 百奥赛图(北京)医药科技股份有限公司 FcRn基因人源化的非人动物及其构建方法和应用
JP7131650B1 (ja) 2021-04-28 2022-09-06 井関農機株式会社 脱穀装置

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68929546T4 (de) 1988-05-27 2007-03-08 Applied Research Systems Ars Holding N.V. Menschlicher Fc-gamma-Rezeptor III
ATE158021T1 (de) * 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5258359A (en) * 1991-08-02 1993-11-02 Monsanto Company Glyphosant-containing herbicidal compositions comprising acetylenic diol rainfastness enhancing agents
EP0663952A4 (de) 1992-09-11 1997-06-11 Univ California Transgene nicht-humane tiere mit zielgerichtet unterbrochenen transduktionsgenen in lymphozyten.
US5877396A (en) * 1993-04-23 1999-03-02 Sloan Kettering Institute For Cancer Research Mice mutant for functional Fc receptors and method of treating autoimmune diseases
US6111166A (en) * 1994-09-19 2000-08-29 Medarex, Incorporated Transgenic mice expressing human Fcα and β receptors
ATE387495T1 (de) 1996-12-03 2008-03-15 Amgen Fremont Inc Vollkommen humane antikörper die egfr binden
US5899312A (en) * 1997-07-22 1999-05-04 Lucent Technologies Inc Anti-fraud string grabbing device
US6676927B1 (en) 1999-01-20 2004-01-13 The Rockefeller University Animal model and methods for its use in the selection of cytotoxic antibodies
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
WO2001079299A1 (en) 2000-04-13 2001-10-25 The Rockefeller University Enhancement of antibody-mediated immune responses
CN101498731A (zh) * 2000-05-18 2009-08-05 日本烟草产业株式会社 抗协同刺激信号转导分子ailim的人单克隆抗体及其药物用途
WO2002006630A1 (en) 2000-07-18 2002-01-24 The Charles Machine Works, Inc. Apparatus and method for maintaining control of a drilling machine
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
FR2822161B1 (fr) 2001-03-15 2003-09-19 Genoway Cellule et animal transgenique modelisant les reponses humaines allergiques mediees par les ige, et leurs utilisations
JP4653915B2 (ja) 2001-10-29 2011-03-16 独立行政法人科学技術振興機構 全身性エリテマトーデスモデル非ヒト動物
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
AU2003233246B2 (en) 2002-06-07 2008-04-10 The Macfarlane Burnet Institute For Medical Research And Public Health Ltd FcyRIIa transgenic animal model for autoimmune disease
JP2004147535A (ja) 2002-10-29 2004-05-27 Japan Science & Technology Agency ギラン・バレー症候群及び／又はフィッシャー症候群発症モデル非ヒト動物
JP2006517096A (ja) 2002-12-16 2006-07-20 ジェネンテック・インコーポレーテッド ヒトｃｄ２０を発現するトランスジェニックマウス
FR2858235B1 (fr) 2003-07-31 2006-02-17 Lab Francais Du Fractionnement Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs
KR101149242B1 (ko) * 2004-01-12 2012-05-25 어플라이드 몰리큘라 에볼류션, 인코포레이티드 Ｆｃ 영역 변이체
DK1802193T3 (da) 2004-10-19 2014-06-10 Regeneron Pharma Fremgangsmåde til frembringelse af en homozygot mus til genetisk modifikation
AU2006299429B2 (en) * 2005-10-03 2012-02-23 Xencor, Inc. Fc variants with optimized Fc receptor binding properties
JP2009529331A (ja) 2006-03-10 2009-08-20 マクロジェニクス，インコーポレーテッド 変異型重鎖を有する抗体の同定および工学的改変ならびにその使用方法
US20080003225A1 (en) 2006-06-29 2008-01-03 Henri Vie Method for enhancing the antibody-dependent cellular cytotoxicity (ADCC) and uses of T cells expressing CD16 receptors
WO2008031056A2 (en) * 2006-09-08 2008-03-13 Medimmune, Llc Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
HU0700534D0 (en) * 2006-11-24 2007-10-29 Mezoegazdasagi Biotechnologiai Transgenic animal with enhanced immune response and method for the preparation thereof
WO2009018411A1 (en) 2007-07-31 2009-02-05 Regeneron Pharmaceuticals, Inc. Human antibodies to human cd20 and method of using thereof
EP2245155A4 (de) * 2007-12-10 2011-05-25 Aliva Biopharmaceuticals Inc Verfahren zum sequentiellen austausch eines zielbereichs mittels homologer rekombination
US20090271884A1 (en) 2008-03-07 2009-10-29 Regeneron Pharmaceuticals, Inc. ES Cell-Derived Mice From Diploid Host Embryo Injection
US20110142857A1 (en) * 2008-07-23 2011-06-16 Rappaport Family Institue For Reseach In The Madical Sciences Efron Street Methods of altering peripheral b cell populations and uses thereof
RS57280B1 (sr) * 2009-12-21 2018-08-31 Regeneron Pharma Humanizovani fc gamma r miševi
US8883496B2 (en) * 2009-12-21 2014-11-11 Regeneron Phamaceuticals, Inc. Humanized FcgR mice

Also Published As

Publication number Publication date
HUE038684T2 (hu) 2018-11-28
RU2012131296A (ru) 2014-01-27
EP3336102A2 (de) 2018-06-20
EP3498730A1 (de) 2019-06-19
CN102762590B (zh) 2015-11-25
LT2516457T (lt) 2018-06-11
US11020495B2 (en) 2021-06-01
DK2516457T3 (en) 2018-06-18
CA2784953A1 (en) 2011-07-14
KR20180058860A (ko) 2018-06-01
PT2516457T (pt) 2018-06-12
AU2014210646B2 (en) 2016-06-23
CA3000246A1 (en) 2011-07-14
US20210346522A1 (en) 2021-11-11
KR101973524B1 (ko) 2019-09-02
JP5595517B2 (ja) 2014-09-24
KR20190045404A (ko) 2019-05-02
EP2516457B1 (de) 2018-03-14
EP3336102A3 (de) 2018-08-01
JP2016093201A (ja) 2016-05-26
JP2013514778A (ja) 2013-05-02
KR101862277B1 (ko) 2018-06-01
US8658853B2 (en) 2014-02-25
CN102762590A (zh) 2012-10-31
US20140154701A1 (en) 2014-06-05
IL220365A0 (en) 2012-08-30
US10426848B2 (en) 2019-10-01
AU2010339863B2 (en) 2014-07-17
MY156743A (en) 2016-03-31
US20240424145A1 (en) 2024-12-26
US9056130B2 (en) 2015-06-16
WO2011084664A1 (en) 2011-07-14
US20140157445A1 (en) 2014-06-05
IL220365A (en) 2016-11-30
HRP20180911T1 (hr) 2018-07-13
CN104232589B (zh) 2018-04-27
US20200061213A1 (en) 2020-02-27
KR20200033981A (ko) 2020-03-30
SG181690A1 (en) 2012-07-30
JP6073840B2 (ja) 2017-02-01
CA3000246C (en) 2021-05-25
AU2014210645B2 (en) 2016-05-19
CY1120316T1 (el) 2019-07-10
KR102178064B1 (ko) 2020-11-12
US20180015185A1 (en) 2018-01-18
TR201808011T4 (tr) 2018-06-21
HK1257001A1 (zh) 2019-10-11
AU2010339863A1 (en) 2012-07-12
EP2516457A1 (de) 2012-10-31
SG10201408415PA (en) 2015-01-29
US20110154512A1 (en) 2011-06-23
JP2014132909A (ja) 2014-07-24
IL261257B (en) 2019-12-31
US20150313195A1 (en) 2015-11-05
CA2784953C (en) 2018-05-22
RU2549695C2 (ru) 2015-04-27
SMT201800296T1 (it) 2018-07-17
JP2014209923A (ja) 2014-11-13
JP5891259B2 (ja) 2016-03-22
CN104232589A (zh) 2014-12-24
PL2516457T3 (pl) 2018-08-31
SI2516457T1 (en) 2018-08-31
EP2516457B9 (de) 2021-09-29
IL271083A (en) 2020-01-30
RS57280B1 (sr) 2018-08-31
IL261257A (en) 2018-10-31
AU2014210645A1 (en) 2014-08-28
AU2014210646A1 (en) 2014-08-28
US20120260357A1 (en) 2012-10-11
US8658154B2 (en) 2014-02-25
ES2671188T3 (es) 2018-06-05
KR20120102138A (ko) 2012-09-17
US9687566B2 (en) 2017-06-27
US9089599B2 (en) 2015-07-28
US12036288B2 (en) 2024-07-16
SG10202011814TA (en) 2021-01-28
KR102092744B1 (ko) 2020-03-24
IL242719A (en) 2017-09-28

Similar Documents

Publication Publication Date Title
BE2015C040I2 (de)
BRPI0925311A2 (de)
BR112012003062A2 (de)
BRPI0924307A2 (de)
BR112012008267A2 (de)
BR112012012396A2 (de)
BR112012000607A2 (de)
BR122021004633A2 (de)
BR112012003080A2 (de)
BR112012012487A2 (de)
BR112012000665A2 (de)
BR122017024704A2 (de)
BR112012003853A2 (de)
BR112012012080A2 (de)
BR112012009797A2 (de)
BR112012009446A2 (de)
BR112012009703A2 (de)
BRPI0924534A2 (de)
BR112012010357A2 (de)
BR112012007656A2 (de)
BR122019005883A2 (de)
BR112012001263A2 (de)
BR112012002627A2 (de)
BR112012000159A2 (de)
BR112012014856A2 (de)